HIV-1 Envelope gp41 Broadly Neutralizing Antibodies: Hurdles for Vaccine Development

Laurent Verkoczy; Garnett Kelsoe; Barton F. Haynes

doi:10.1371/journal.ppat.1004073

Loading metrics

Open Access

Pearls provide concise, practical and educational insights into topics that span the pathogens field.

See all article types »

HIV-1 Envelope gp41 Broadly Neutralizing Antibodies: Hurdles for Vaccine Development

Laurent Verkoczy,

Affiliations Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, United States of America, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, United States of America, Department of Pathology, Duke University School of Medicine, Durham, North Carolina, United States of America
⨯
Garnett Kelsoe,

Affiliations Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, United States of America, Department of Immunology, Duke University School of Medicine, Durham, North Carolina, United States of America
⨯
Barton F. Haynes

* E-mail: Barton.haynes@duke.edu

Affiliations Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, United States of America, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, United States of America, Department of Immunology, Duke University School of Medicine, Durham, North Carolina, United States of America
⨯

HIV-1 Envelope gp41 Broadly Neutralizing Antibodies: Hurdles for Vaccine Development

Laurent Verkoczy,
Garnett Kelsoe,
Barton F. Haynes

Published: May 22, 2014
https://doi.org/10.1371/journal.ppat.1004073

About the Authors

Laurent Verkoczy

Affiliations Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, United States of America, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, United States of America, Department of Pathology, Duke University School of Medicine, Durham, North Carolina, United States of America

Garnett Kelsoe

Affiliations Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, United States of America, Department of Immunology, Duke University School of Medicine, Durham, North Carolina, United States of America

Barton F. Haynes

* E-mail: Barton.haynes@duke.edu

Affiliations Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, United States of America, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, United States of America, Department of Immunology, Duke University School of Medicine, Durham, North Carolina, United States of America

Competing Interests

The authors have declared that no competing interest exist.

Subject Areas
?

For more information about PLOS Subject Areas, click here.
We want your feedback. Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!

HIV-1
Is the Subject Area "HIV-1" applicable to this article?

Thanks for your feedback.
B cells
Is the Subject Area "B cells" applicable to this article?

Thanks for your feedback.
Antibodies
Is the Subject Area "Antibodies" applicable to this article?

Thanks for your feedback.
HIV vaccines
Is the Subject Area "HIV vaccines" applicable to this article?

Thanks for your feedback.
Antigens
Is the Subject Area "Antigens" applicable to this article?

Thanks for your feedback.
Vaccine development
Is the Subject Area "Vaccine development" applicable to this article?

Thanks for your feedback.
Immune response
Is the Subject Area "Immune response" applicable to this article?

Thanks for your feedback.
Immune tolerance
Is the Subject Area "Immune tolerance" applicable to this article?

Thanks for your feedback.